biologics

NEW DELHI: Indian firms hoping to ride the global biologics boom are finding the path far tougher than expected, as China tightens its grip further on biotech supply chains. Recent data suggests Chinese companies have bagged more than half of several recent project deals from US biotech companies, underscoring the challenge for Indian players trying…